Search Results - "Liu, Aston"

State-of-the-art technologies for rapid and high-throughput sample preparation and analysis of N-glycans from antibodies by Aich, Udayanath, Lakbub, Jude, Liu, Aston

“…Glycosylation is a PTM that occurs during production of many protein‐based biologic drugs and can have a profound impact on their biological, clinical, and…”
Get full text

A novel method for removing polyethyleneimine from biopharmaceutical samples: improving assay sensitivity of residual DNA qPCR by Zhang, Shu-Min, Roberts, Matthew, Jones, Marisa, Zeitler, Jacob, Kilby, Greg, Liu, Aston, White, John R

“…Polyethyleneimine (PEI) is a flocculent that is widely used in the downstream purification of monoclonal antibodies. It is an in-process residual that is…”
Get full text

An Integrated Solution-Based Rapid Sample Preparation Procedure for the Analysis of N-Glycans From Therapeutic Monoclonal Antibodies by Aich, Udayanath, Liu, Aston, Lakbub, Jude, Mozdzanowski, Jacek, Byrne, Michael, Shah, Nilesh, Galosy, Sybille, Patel, Pramthesh, Bam, Narendra

“…Consistent glycosylation in therapeutic monoclonal antibodies is a major concern in the biopharmaceutical industry as it impacts the drug's safety and efficacy…”
Get more information

Understanding the Conformational Impact of Chemical Modifications on Monoclonal Antibodies with Diverse Sequence Variation Using Hydrogen/Deuterium Exchange Mass Spectrometry and Structural Modeling by Zhang, Aming, Hu, Ping, MacGregor, Paul, Xue, Yu, Fan, Haihong, Suchecki, Peter, Olszewski, Leonard, Liu, Aston

“…Chemical modifications can potentially induce conformational changes near the modification site and thereby impact the safety and efficacy of protein…”
Get full text

A Fully Integrated Online Platform For Real Time Monitoring Of Multiple Product Quality Attributes In Biopharmaceutical Processes For Monoclonal Antibody Therapeutics by Liu, Yang, Zhang, Chi, Chen, Jiangchao, Fernandez, Janice, Vellala, Pragna, Kulkarni, Tanmay A, Aguilar, Isaiah, Ritz, Diana, Lan, Kevin, Patel, Pramthesh, Liu, Aston

“…In response to FDA's call for Quality by Design (QbD) in biopharmaceutical product development, the biopharmaceutical industry has been developing highly…”
Get more information

Characterizing Novel Modifications of a Therapeutic Protein Using Ultra Performance Liquid Chromatography–Tandem Mass Spectrometry, Sedimentation Velocity Analytical Ultracentrifugation, and Structural Modeling by Shi, Yu, Hong, Xuan, Fan, Haihong, Wu, Zhuchun, Liu, Aston

“…Heterogeneity of biopharmaceutical products is common due to various co- and post-translational modifications and degradation events that occur during the…”
Get full text

A heat shock protein based polyvalent vaccine targeting HSV-2: CD4+ and CD8+ cellular immunity and protective efficacy by Mo, Annie, Musselli, Cristina, Chen, Hong, Pappas, John, LeClair, Kenneth, Liu, Aston, Chicz, Roman M, Truneh, Alemseged, Monks, Stephen, Levey, Daniel L, Srivastava, Pramod K

“…Abstract Efforts to develop a subunit vaccine against genital herpes have been hampered by lack of knowledge of the protective antigens of HSV-2, the causative…”
Get full text

A heat shock protein based polyvalent vaccine targeting HSV-2: CD4 super(+ and CD8) super(+) cellular immunity and protective efficacy by Mo, Annie, Musselli, Cristina, Chen, Hong, Pappas, John, LeClair, Kenneth, Liu, Aston, Chicz, Roman M, Truneh, Alemseged, Monks, Stephen, Levey, Daniel L, ivastava, Pramod K

“…Efforts to develop a subunit vaccine against genital herpes have been hampered by lack of knowledge of the protective antigens of HSV-2, the causative agent of…”
Get full text